Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-019-02431-8
Abstract: The safety of anti-programmed cell death 1 (PD-1) antibody for patients with preexisting interstitial lung disease (ILD) remains unknown. The aim of this study was to evaluate the dependence of preexisting ILD on anti-PD-1 antibody-induced… read more here.
Keywords: preexisting ild; anti antibody; antibody; patients preexisting ... See more keywords
Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease
Sign Up to like & getrecommendations! Published in 2019 at "Medical Oncology"
DOI: 10.1007/s12032-019-1274-0
Abstract: In non-small cell lung cancer (NSCLC) patients, the expression of tumor programmed death ligand 1 (PD-L1) is an important parameter for deciding the timing of the use of anti-programmed cell death 1 (PD-1) antibody. There… read more here.
Keywords: preexisting ild; lung; patients preexisting; tumor expression ... See more keywords